|
|
‒ , . - -, . 1 ‒ , . , .
: . , , , , , .
.
, , . . 4
B1, B2 9, . 5
:
- :
, . (, , , ) 7 , . , , , . 8
, , . . . , , -, , II . 9 , . 10
I , , , , . 50 . .
|
: , |
|
, . , , .
, 1 2 , , . , , , .
. , I .
, . , , , , . . , .
, , , , , . , . . , , , .
, .
, .
:
:
10 10 14.
, , . .
1 :
, 2 , :
. , , , . , , , .
:
. , . 3,3 5,5 /.
, . . .
:
: . , .
! , : , , . .
. . . , , . , .
:
.
.
https://fr-dc.ru/hormones/progesteron/nedostatok-u-zhenshin.html .
. , , , , , .
, . , , .
:
. , .
:
, , . . : , , , , .
:
|
|
|
, , ,
300 . . ( , ), .
, , . , , . .
-ո (Dae-Hyeong Kim).
, . , . 250 . , , , .
15 , . , . , . , .
, Nature Nanotechnology, , , .
, .
, , , .
" ", .
, , .
: , . .
|
2 , |
|
. , , 2 (2) 2 . . 2 2009 2011 2011 2014 . ( 1955 , 1351 2 604 ) 2 , (379 ). 2 , >6 ., . . 2, , , 2 ( 28,51,2% vs 38,02,5%, p (+17,9%), 2 (+19,3%). ( 70-75% ) . 2 2 . . , 2, 2 . , . .
Aims. To study at greater than before material the prevalence of type 2 diabetes (T2DM) in relatives of suffering from T2DM patients with cancer and compare the features of antidiabetic therapy in cancer patients with a familial and non-familial form of diabetes. Materials and Methods. Information about diabetes history in family was collected during two subsequent periods (May 2009-February 2011 and March 2011-July 2014 years) in cancer patients (totally,1955 people; 1351 of them with T2DM and 604 without diabetes), as well as in patients with T2DM without cancer (n=379). All patients answered questions about diabetes in their mothers, fathers, siblings, and other relatives. In cancer patients with T2DM, data on the type of antidiabetic therapy for at least 6 months prior to enrolling into the hospital were collected. Results. A lower frequency of family diabetes in diabetic patients with cancer (28,51,2% vs 38,02,5%, p cancer ) was revealed. By 2011-2014 the prevalence of family diabetes was grown significantly and virtually in a similar degree in both groups (+17,9% in T2DM with cancer and +19,3% in T2DM without cancer ). T2DM patients with cancer and family history of diabetes used metformin prior hospitalization more often than same patients without familial T2DM. Conclusion. Reaffirming the earlier data on more infrequent occurrence of family diabetes in T2DM patients with cancer compared with T2DM patients without cancer , we were able to demonstrate roughly the same increase in the detection of familial diabetes in these groups of patients in a rather short period of time. The use of metformin one of the potential factors contributing to the probable and unexpected decrease of cancer risk in T2DM patients with familial type of diabetes. Other possible causes of this phenomenon deserve further study in view of the growing epidemic of diabetes and obesity.
. 2015;18(3):77-84
2 ,
..1, ..2, ..1, ..1
. .. , -
( ..., . .. ) 2 122 . .. , -
( ..., . .. )
. , , 2 (2) 2 .
. 2 2009 2011 2011 2014 . ( 1955 , 1351 2 604 ) 2 , (379 ). 2 , >6 , .
. 2, , , 2 ( 28,51,2% vs 38,02,5%, p
Results. A lower frequency of family diabetes in diabetic patients with cancer (28,51,2% vs 38,02,5%, p , ? .
2 ( ), 2 ( )
, % p
2 1351 28,5 , ? .
( %) 2 15,4 16,7
* .
2 . , ( %) , 2 2 - (. 2).
2, , , , , , -, . , 2013 2014 . 346 2 (113 - 233 ) 75,2+4,1% 70,4+3,0%, 11,5+3,0% 17,6+2,5%, / 6,2+2,1% 2,6+1,0% 7,1+1,7% 9,4+1,9% . , , 2 2 , , (. 3). - ,
, , [2] - .
, (. 1), [18, 19], [16], , 2, . 2 (. 2). .
, 2 [10, 11, 22, 23], , . , ( ) [24]. , [25].
, ,
6 , %
(2) X2 =1)
2 (=199) 2 (=295)
21,1 34,9 9,32 =0,0023
() 14,0 10,8 1,16 =0,2821
() 31,1 21,7 5,60 =0,0180
+ 15,6 15,6 0,00 =0,9963
13,1 12,5 0,03 =0,8643
DPP-4 4,0 4,4 0,04 =0,8345
: DPP-4 - -4
. 2015;18(3):77-84
[13, 23]. , , , 56 , , () , , 1. [19, 26], [23] [27, 28], , 2, .
[29]. , , [8]. , , , 2 , , , , ( ) , , [7, 30]. , , 2, .
, , 90- , [14]. 654 ( 2) , , , , 1,37 [31], : 7 49 (14,3%) 2 [32]. : 55 55 [15].
. . [16]. , 50% , . , 2 (, , ),
( 1,04) ( 1,37) . , ( ) 2 , [16], (. 1). [18], , , 2, [33], . . [16], , .
, , ( , , ) 2 , - (. 2). , , ( ). , 2 , , , 2 (. 3). - [18], , ( ) 1819% (. 2). ( , , [34, 35], ), , , , [18], .
, , , , + , , , [16, 19] . , , , 2+, , 2, ( ) , -
. 2015;18(3):77-84
, , , - -6 , 2. , , 2 , , , 2 [36] (. [11]).
, (, , ) , + (. 2), , , , 2 [14]. , , , vice versa, [24, 37, 38].
, . , . , , , , [37].
, 2011 . (n=436) , , 2014 . (n=915), [18] . , , , 20112014 . , 2, 2 , (. 2 ). , , 2 (. 1), (, 62,00,4 62,30,3 ) .
, , -
, .. , , -, ( ) , -, , - , 2, 2 [36]. , (., , . 3) , .
, . , , [25], [13, 23]. , , , genetic risk score 2 9% , , [39]. , , 2 [23], .
, , , , , 2 . , EPIC-InterAct, 2, [23]. , , , , 2, , , , , [40]. , , , [27, 28], .
, ,
, 2, , 2 , - .
. 2015;18(3):77-84
( 12-04-00084).
1. .., .. . . -.; 2003. - .455. [Dedov II, Shestakova MV. Diabetes mellitus. Manual for physicians. Moscow; 2003. 455 p. (in Russ.)]
2. .. 2 . : . . 2- , . - .: -; 2014. - 1032 . [Ametov A.S. Saharnyj diabet 2 tipa. Problemy i reshenija. 2 nd ed. Moscow: GEOTAR-Media; 2014. (in Russ.)]
3. Ginter E, Simko V. Type 2 diabetes mellitus, pandemic in 21st century. Adv Exp Med Biol. 2012;771:42-50. doi: 10.1007/978-1-4614-5441-0_6
4. Scheen AJ, Van Gaal LF. Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes. Lancet Diabetes Endocrinol. 2014;2(11):911-922. doi: 10.1016/S2213-8587(14)70004-X
5. Zimmet P, Alberti KGMM, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001 ;414(6865):782-787. doi: 10.1038/414782a
6. Gregg E. Obesity, diabetes, and the moving targets of healthy-years estimation. Lancet Diabetes Endocrinol. 2015;3(2):93-94. doi: 10.1016/S2213-8587(14)70242-6
7. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care. 2010;33(7):1674-1685. doi: 10.2337/dc10-0666
8. Tsilidis KK, Kasimis JC, Lopez DS, et al. Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ. 2015;350:g7607. doi: 10.1136/bmj.g7607
9. Groop L, Forsblom C, Lehtovirta M, et al. Metabolic consequences of a family history of NIDDM (the Botnia study): evidence for sex-specific parental effects. Diabetes. 1996;45(1 1):1585-1593. doi: 10.2337/diabetes.45.11.1585
10. Meigs JB, Cupples LA, Wilson PW. Parental transmission of type 2 diabetes: the Framingham Offspring Study. Diabetes. 2000;49(12):2201-2207. doi: 10.2337/diabetes.49.12.2201
1 1. Papazafiropoulou A, Sotiropoulos A, Skliros E, et al. Familial history of diabetes and clinical characteristics in Greek subjects with type 2 diabetes. BMC Endocr Disord. 2009;9:12. doi: 10.1186/1472-6823-9-12
12. .., .., .., . . // . - 2014. - . 1 7. - 1 - . 8-14. doi: 10.14341/DM201418-14 [Misnikova IV, Dreval AV, Kovaleva YA, et al. Optimizing screening procedures for early detection of glycemic disorders. Diabetes mellitus. 2014;17(1):8-14.] doi: 10.14341/DM201418-14
13. Vassy JL, Shrader P, Jonsson A, et al. Association between parental history of diabetes and type 2 diabetes genetic risk scores in the PPP-Botnia and Framingham Offspring Studies. Diabetes Res Clin Pract. 2011;93(2):e76-9. doi: 10.1016/j.diabres.2011.04.013
14. Toyoshima H, Hayashi S, Hashimoto S, et al. Familial aggregation and covariation of diseases in a Japanese rural community: comparison of stomach cancer with other diseases. Ann Epidemiol. 1997;7(7):446-451. doi: 10.1016/S1047-2797(97)00077-X
15. Brauer PM, McKeown-Eyssen GE, Jazmaji V, et al. Familial Aggregation of Diabetes and Hypertension in a Case-Control Study of Colorectal Neoplasia. American Journal of Epidemiology. 2002;156(8):702-713. doi: 10.1093/aje/kwf112
16. Hemminki K, Li X, Sundquist J, Sundquist K. Risk of Cancer Following Hospitalization for Type 2 Diabetes. The Oncologist. 2010;15(6):548-555. doi: 10.1634/theoncologist.2009-0300
17. .., .., .., . . // . - 2011. - . 57. - 4 - . 443-447 [Bershtein LM, Boriakina MP, Teslenko SI, et al. Familial diabetes frequency as a factor in diabetics suffering from cancer. Voprosy Onkologii 2011;57(4):443-447.] PMID: 22191231
18. Berstein L, Boyarkina M, Teslenko S. Familial diabetes is associated with reduced risk of cancer in diabetic patients: a possible role for metformin. Med Oncol. 2012;29(2):1308-1313. doi: 10.1007/s12032-01 1-9840-0
19. .., .., .., . . // . -2013. - . 59. - 3 - . 352-357. [Bershtein LM, Vasil'ev DA, Boiarkina MP, et al. Family diabetes and its consequences in cancer patients. Voprosy Onkologii 2013;59(3):352-357]. PMID: 23909037
20. WHO/Europe Diabetes: Data and Statistics. Available from: http://www. euro.who.int/en/health-topics/noncommunicable-diseases/diabetes/data-and-statistics
21. Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycaemia. Report of a WHO/IDF consultation. Geneva, Switzerland, 2008, 50 pp.
22. Annis AM, Caulder MS, Cook ML, Duquette D. Family History, Diabetes, and Other Demographic and Risk Factors Among Participants of the National Health and Nutrition Examination Survey 1999-2002. Preventing Chronic Disease. 2005;2(2):A19
23. Scott RA, Langenberg C, Sharp SJ, et al. The link between Family History and risk of Type 2 Diabetes is Not Explained by Anthropometric, Lifestyle or Genetic Risk Factors: the EPIC-InterAct Study. Diabetologia. 2013;56(1):60-69. doi: 10.1007/s00125-012-2715-x
24. Valdez R. Detecting Undiagnosed Type 2 Diabetes: Family History as a Risk Factor and Screening Tool. Journal of diabetes science and technology. 2009;3(4):722-726. doi: 10.1177/193229680900300417
25. Eades S, Bishop M, Newton R, et al. Genetics: what's it got to do with family health care? J Fam Health Care. 2010;20(2):42-44.
26. Drong AW, Lindgren CM, McCarthy MI. The Genetic and Epigenetic Basis of Type 2 Diabetes and Obesity. Clinical Pharmacology & Therapeutics. 2012;92(6):707-715. doi: 10.1038/clpt.2012.149
27. Jensen MD. Brown adipose tissue - not as hot as we thought. J Physiol. 2015;593(3):489. doi:10.1113/jphysiol.2014.287979
28. Berstein LM. Cancer and heterogeneity of obesity: a potential contribution of brown fat. Future Oncol. 2012;8(12):1537-1548. doi: 10.2217/fon.12.150
29. Wild CP. The Role of Cancer Research in Noncommunicable Disease Control. JNCI Journal of the National Cancer Institute. 2012;104(14):1051-1058. doi: 10.1093/jnci/djs262
30. Vigneri P, Frasca F, Sciacca L, et al. Diabetes and cancer. Endocrine-related cancer. 2009;16(4):1 103-1 123. doi: 10.1677/erc-09-0087
31. Austin MA, Kuo E, Van Den Eeden SK, et al. Family History of Diabetes and Pancreatic Cancer as Risk Factors for Pancreatic Cancer: The PACIFIC Study. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2013;22(10):10.1 158/1055-9965.EPI-1113-0518. doi: 10.1158/1055-9965.EPI-13-0518
32. .., .. . // . - 2013. - . 4. - 58 - . 36-39.[Kashintsev AA, Kokhanenko NYu. The relationship between diabetes and pancreatic cancer. Sibirskij OnkologicheskijZhurnal. 2013; 4(58): 36-39].
33. Stephansson O, Granath F, Ekbom A, Michels KB. Risk of breast cancer among daughters of mothers with diabetes: a population-based cohort study. Breast Cancer Research: BCR. 2010;12(1):R14-R14. doi: 10.1186/bcr2481
34. Gandini S, Puntoni M, Heckman-Stoddard BM, et al. Metformin and Cancer Risk and Mortality: A Systematic Review and Meta-analysis Taking into Account Biases and Confounders. Cancer Prevention Research. 2014;7(9):867-885. doi: 10.1158/1940-6207.capr-13-0424
35. Berstein LM. Metformin in obesity, cancer and aging: addressing controversies. Aging (Albany NY). 2012;4(5):320-329. PMID: 22589237.
36. .., .., .., . - : . // . - 2013. - 2. - . 29-34. [Bershtein LM,
. 2015;18(3):77-84
Vasil'ev DA, Poroshina TE, et al. Hormonal-metabolic pattern of postmenopausal females with new onset of diabetes mellitus type 2: the role of cancer and hereditary predisposition to diabetes. Vestnik Rossjskoi' Akademii Meditsinskih Nauk. 2013;(2):29-34]. PMID:23819326
37. Harrison TA, Hindorff LA, Kim H, et al. Family history of diabetes as a potential public health tool. American Journal of Preventive Medicine. 2003;24(2):152-159. doi: 10.1016/S0749-3797(02)00588-3
38. Li H, Oldenburg B, Chamberlain C, et al. Diabetes prevalence and determinants in adults in China mainland from 2000 to 2010: A systematic
review. Diabetes research and clinical practice.2012;98(2):226-235. doi: 10.1016/j.diabres.2012.05.010
Raghavan S, Porneala B, McKeown N, et al. Metabolic factors and genetic risk mediate familial type 2 diabetes risk in the Framingham Heart Study. Diabetologia. 2015;58(5):988-996. doi: 10.1007/s00125-015-3498-7 Ning F, Pang Z, Laatikainen T, et al. Joint Effect of Family History of Diabetes with Obesity on Prevalence of Type 2 Diabetes Mellitus Among Chinese and Finnish Men and Women. Canadian Journal of Diabetes. 2013;37(2):65-71. doi: 10.1016/j.jcjd.2012.12.001
..., ., - . .. -,
-, N122 . .. , -,
..., ... , - . .. , -, -, .. , - . .. , -,
|
: | [1] |